Cancer Supportive Care Drugs Market Size, Share, Growth Analysis Report 2032
Cancer Supportive Care Drugs Market by Drug Class (Granulocyte-Colony Stimulating Factors (G-CSF), Erythropoietin-Stimulating Agents (ESA), Antiemetics, Bisphosphonates, Opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAID), and Others), and by Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Cancers), and By Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2024 - 2032
Category: Healthcare Report Format : PDF
Pages: 204 Report Code: ZMR-4902
Published Date: Aug-2024 Status : Published
| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 21.0 Billion | USD 25.31 Billion | 2.1% | 2023 |
Table Of Content
- Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
- 2.2. Cancer Supportive Care Drugs Market: Snapshot
- Chapter 3. Cancer Supportive Care Drugs Market - Industry Analysis
- 3.1. Cancer Supportive Care Drugs Market: Market Dynamics
- 3.2. Market Drivers
- 3.2.1. Driver 1
- 3.2.2. Driver 2
- 3.3. Restraints
- 3.3.1. Restraint 1
- 3.3.2. Restraint 2
- 3.4. Opportunity
- 3.4.1. Government funding and support
- 3.5. Porter's Five Forces Analysis
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis By Drug Class
- 3.6.2. Market attractiveness analysis By Cancer Type
- 3.6.3. Market attractiveness analysis by Region
- Chapter 4. Cancer Supportive Care Drugs Market- Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global Cancer Supportive Care Drugs Market: company market share, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New Drug Class launches
- 4.2.3. Agreements, partnerships, collaborations and joint ventures
- 4.2.4. Research and development and Regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Cancer Supportive Care Drugs Market -Drug Class Analysis
- 5.1. Global Cancer Supportive Care Drugs Market overview: By Drug Class type
- 5.1.1. Global Cancer Supportive Care Drugs Market share, By Drug Class,2018 and 2025
- 5.2. Granulocyte-Colony Stimulating Factors (G-CSF)
- 5.2.1. Global Cancer Supportive Care Drugs Market by Granulocyte-Colony Stimulating Factors (G-CSF), 2016-2025 (USD Million)
- 5.3. Erythropoietin-Stimulating Agents (ESA)
- 5.3.1. Global Cancer Supportive Care Drugs Market by Erythropoietin-Stimulating Agents (ESA), 2016-2025 (USD Million)
- 5.4. Antiemetic's
- 5.4.1. Global Cancer Supportive Care Drugs Market by Antiemetic's, 2016-2025 (USD Million)
- 5.5. Bisphosphonates
- 5.5.1. Global Cancer Supportive Care Drugs Market by Bisphosphonates, 2016-2025 (USD Million)
- 5.6. Opioids
- 5.6.1. Global Cancer Supportive Care Drugs Market by Opioids, 2016-2025 (USD Million)
- 5.7. Non-Steroidal Anti-Inflammatory Drugs (NSAID)
- 5.7.1. Global Cancer Supportive Care Drugs Market by Non-Steroidal Anti-Inflammatory Drugs (NSAID), 2016-2025 (USD Million)
- 5.8. Others
- 5.8.1. Global Cancer Supportive Care Drugs Market by others, 2016-2025 (USD Million)
- 5.1. Global Cancer Supportive Care Drugs Market overview: By Drug Class type
- Chapter 6. Global Cancer Supportive Care Drugs Market -Cancer Type Analysis
- 6.1. Global Cancer Supportive Care Drugs Market overview: By Cancer Type
- 6.1.1. Global Cancer Supportive Care Drugs Market share, By Cancer Type, 2018 and 2025
- 6.2. Breast Cancer
- 6.2.1. Global Cancer Supportive Care Drugs Market By Breast Cancer, 2016-2025 (USD Million)
- 6.3. Lung Cancer
- 6.3.1. Global Cancer Supportive Care Drugs Market By Lung Cancer, 2016-2025 (USD Million)
- 6.4. Melanoma
- 6.4.1. Global Cancer Supportive Care Drugs Market By Melanoma, 2016-2025 (USD Million)
- 6.5. Prostate Cancer
- 6.5.1. Global Cancer Supportive Care Drugs Market By Prostate Cancer, 2016-2025 (USD Million)
- 6.6. Others
- 6.6.1. Global Cancer Supportive Care Drugs Market by Other Cancer Types, 2016-2025 (USD Million)
- 6.1. Global Cancer Supportive Care Drugs Market overview: By Cancer Type
- Chapter 7. Global Cancer Supportive Care Drugs Market - Regional Analysis
- 7.1. Global Cancer Supportive Care Drugs Market overview: by Region
- 7.1.1. Global Cancer Supportive Care Drugs Marketshare, by Region, 2018 and 2025
- 7.2. North America
- 7.2.1. North America Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
- 7.2.2. North America Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.2.3. North America Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.2.4. The U.S.
- 7.2.4.1. The U.S.Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.2.4.2. The U.S.Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.2.5. Rest of North America
- 7.2.5.1. Rest of North America Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.2.5.2. Rest of North America Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
- 7.3.2. Europe Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.3.3. Europe Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.3.4. UK
- 7.3.4.1. U.K.Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.3.4.2. U.K.Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.3.5. France
- 7.3.5.1. France Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.3.5.2. France Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.3.6. Germany
- 7.3.6.1. Germany Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.3.6.2. Germany Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.3.7. Rest of Europe
- 7.3.7.1. Rest of EuropeCancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.3.7.2. Rest of EuropeCancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
- 7.4.2. Asia Pacific Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.4.3. Asia Pacific Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.4.4. China
- 7.4.4.1. China Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.4.4.2. China Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.4.5. Japan
- 7.4.5.1. Japan Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.4.5.2. Japan Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.4.6. India
- 7.4.6.1. India Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.4.6.2. India Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.4.7. Rest of Asia Pacific
- 7.4.7.1. Rest of Asia Pacific Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.4.7.2. Rest of Asia Pacific Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
- 7.5.2. Latin America Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.5.3. Latin America Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.5.4. Brazil
- 7.5.4.1. Brazil Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.5.4.2. Brazil Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.5.5. Rest of LatinAmerica
- 7.5.5.1. Rest of LatinAmerica Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.5.5.2. Rest of LatinAmerica Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.6. The Middle East and Africa
- 7.6.1. The Middle East and Africa Cancer Supportive Care Drugs Market, 2016-2025 (USD Million)
- 7.6.2. The Middle East and Africa Cancer Supportive Care Drugs Market revenue, By Drug Class,2016-2025 (USD Million)
- 7.6.3. The Middle East and Africa Cancer Supportive Care Drugs Market revenue, By Cancer Type, 2016-2025 (USD Million)
- 7.1. Global Cancer Supportive Care Drugs Market overview: by Region
- Chapter 8. Company Profiles
- 8.1. Johnson & Johnson
- 8.1.1. Overview
- 8.1.2. Financials
- 8.1.3. Drug Class Portfolio
- 8.1.4. Business Strategy
- 8.1.5. Recent Developments
- 8.2. Amgen
- 8.2.1. Overview
- 8.2.2. Financials
- 8.2.3. Drug Class Portfolio
- 8.2.4. Business Strategy
- 8.2.5. Recent Developments
- 8.3. Merck
- 8.3.1. Overview
- 8.3.2. Financials
- 8.3.3. Drug Class Portfolio
- 8.3.4. Business Strategy
- 8.3.5. Recent Developments
- 8.4. Heron Pharma
- 8.4.1. Overview
- 8.4.2. Financials
- 8.4.3. Drug Class Portfolio
- 8.4.4. Business Strategy
- 8.4.5. Recent Developments
- 8.5. Roche
- 8.5.1. Overview
- 8.5.2. Financials
- 8.5.3. Drug Class Portfolio
- 8.5.4. Business Strategy
- 8.5.5. Recent Development
- 8.6. Helsinn Healthcare
- 8.6.1. Overview
- 8.6.2. Financials
- 8.6.3. Drug Class Portfolio
- 8.6.4. Business Strategy
- 8.6.5. Recent Development
- 8.7. Tesaro
- 8.7.1. Overview
- 8.7.2. Financials
- 8.7.3. Drug Class Portfolio
- 8.7.4. Business Strategy
- 8.7.5. Recent Development
- 8.8. Company08
- 8.8.1. Overview
- 8.8.2. Financials
- 8.8.3. Drug Class Portfolio
- 8.8.4. Business Strategy
- 8.8.5. Recent Development
- 8.9. Company09
- 8.9.1. Overview
- 8.9.2. Financials
- 8.9.3. Drug Class Portfolio
- 8.9.4. Business Strategy
- 8.9.5. Recent Development
- 8.1. Johnson & Johnson
Methodology
FrequentlyAsked Questions
Cancer supportive care drugs are medications used to manage side effects of cancer treatment. They help reduce pain, nausea, fatigue, and improve quality of life.
The global cancer supportive care drugs market is expected to be driven by the rising cancer incidence, need to manage chemotherapy side effects, and focus on improving patient quality of life during treatment.
According to study, the global cancer supportive care drugs market size was worth around USD 21.0 Billion in 2023 and is predicted to grow to around USD 25.31 Billion By 2032.
The global cancer supportive care drugs market is expected to grow at a Compound Annual Growth Rate (CAGR) of around CAGR 2.1% during the forecast period from 2024-2032.
The global cancer supportive care drugs industry is projected to be challenged by Key challenges include demonstrating clinical benefit alongside oncology therapies, managing drug interactions, and reimbursement pressure. Pricing scrutiny and varied patient response affect uptake.
The Opportunities include managing chemotherapy side effects, improving patient quality of life, and expanding use alongside combination therapies. Rising cancer prevalence and outpatient care drive steady demand will offer significant growth opportunities in the cancer supportive care drugs market.
Drugs for managing chemotherapy side effects; focus on quality-of-life improvement; combination supportive therapies are the emerging trends and innovations impacting the cancer supportive care drugs market.
The global cancer supportive care drugs market is expected to be led by North America during the forecast period.
Some of the prominent players operating in the global cancer supportive care drugs market are; Johnson & Johnson, Amgen, Merck, Heron Pharma, Roche, Helsinn Healthcare, and Tesaro and others.
The report explores crucial aspects of the cancer supportive care drugs market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
HappyClients
